ResMed: Accelerating Global Expansion With Strong Growth in Europe & China! 

ResMed’s fourth quarter fiscal year 2025 results present a balanced outlook for potential investors, highlighting a mix of strong financial performance and strategic challenges. The company reported a 10% year-over-year increase in headline revenue and a 230 basis point expansion in gross margin, indicating strong operational execution and cost management. This growth was fueled by robust demand across its product and ReSupply portfolios, with notable performance in both the U.S., Canada, Latin America, and internationally. The results also reflect a positive impact from recent acquisitions, including VirtuOx, which contributes to ResMed’s ongoing capability to enhance its diagnostic offerings in sleep health.